CD274 and non-small cell lung carcinoma: This was followed by the study of Hellmann et al., using the same CAPP-seq technique to perform ctDNA analysis, to assess the risk of progression after long-term response to PD-(L)1 blockage in non-small cell lung cancer (NSCLC) [23].